# FWO DMP Template - Flemish Standard Data Management Plan

# Version KU Leuven

Project supervisors (from application round 2018 onwards) and fellows (from application round 2020 onwards) will, upon being awarded their project or fellowship, be invited to develop their answers to the data management related questions into a DMP. The FWO expects a **completed DMP no later than 6 months after the official start date** of the project or fellowship. The DMP should not be submitted to FWO but to the research co-ordination office of the host institute; FWO may request the DMP in a random check.

At the end of the project, the **final version of the DMP** has to be added to the final report of the project; this should be submitted to FWO by the supervisor-spokesperson through FWO’s e-portal. This DMP may of course have been updated since its first version. The DMP is an element in the final evaluation of the project by the relevant expert panel. Both the DMP submitted within the first 6 months after the start date and the final DMP may use this template.

The DMP template used by the Research Foundation Flanders (FWO) corresponds with the Flemish Standard Data Management Plan. This Flemish Standard DMP was developed by the Flemish Research Data Network (FRDN) Task Force DMP which comprises representatives of all Flemish funders and research institutions. This is a standardized DMP template based on the previous FWO template that contains the core requirements for data management planning. To increase understanding and facilitate completion of the DMP, a standardized **glossary** of definitions and abbreviations is available via the following [link](https://www.fwo.be/media/1024841/glossary-flemish-standard-data-management-plan.pdf).

|  |  |
| --- | --- |
| 1. **General Project Information** | |
| Name Grant Holder & ORCID | My Luong Vuong, 0000-0001-9203-6745 |
| Contributor name(s) (+ ORCID) & roles |  |
| Project number [[1]](#footnote-1) & title | 1SH6A24N, Joint pharmacometrics modeling of antimicrobial exposure, biomarkers, and clinical outcome assessments to improve the in silico exploration of dose optimization strategies in critically ill patients |
| Funder(s) GrantID [[2]](#footnote-2) |  |
| Affiliation(s) | x KU Leuven  ☐ Universiteit Antwerpen  ☐ Universiteit Gent  ☐ Universiteit Hasselt  ☐ Vrije Universiteit Brussel  ☐ Other:  ROR identifier KU Leuven: 05f950310 |
| Please provide a short project description | Dosage regimens of antimicrobial drugs predominantly stem from in vitro and animal studies. Critically ill patients display altered, highly variable drug concentration-time profiles in their bodies (i.e., pharmacokinetics; PK). Therefore, therapeutic drug monitoring (TDM) has been used to individualize dosing in this vulnerable patient group. TDM guides dosing based on drug concentration measurements, thereby maximizing the chance to meet desired exposure targets. However, the successful attainment of an exposure target is not necessarily reflected in a favorable clinical outcome. Despite the growing interest in TDM in the last decade, the quality of evidence remains low. We believe that dose optimization practices will only reach their optimal success when combining TDM with the monitoring of biomarkers and clinical markers of surrogate response such as disease activity scores (i.e., pharmacodynamics; PD). Therefore, we will develop state-of-the-art pharmacometrics models to quantitatively describe, understand, and predict the relationship between antimicrobial drug dose, drug exposure, biomarker/surrogate responses, and clinically relevant endpoints. We propose a disease/PD-oriented modeling and simulation approach based on real-world data of critically ill patients on antimicrobial treatments. We hypothesize that our population PKPD models will facilitate more efficient drug dosing, including their application in PKPD model-informed precision dosing. |

|  |  |
| --- | --- |
| 1. **Research Data Summary** | |
| List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data [[3]](#footnote-3).   |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | |  | | | | *Only for digital data* | *Only for digital data* | *Only for digital data* | *Only for physical data* | | Dataset Name | Description | New or Reused | Digital or Physical | Digital Data Type | Digital Data Format | Digital Data Volume (MB, GB, TB) | Physical Volume | | M@tric | Big clinical outcome data in 3 ICUs. | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | NA | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA |  | | Meropenem\_ECMO\_ICU | Meropenem in ICU patients with/without ECMO | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | .xlsx | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA |  | | Ceftriaxone\_CAP\_ICU | Meropenem in ICU patients with severe community-acquired pneumonia | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | .xlsx | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA |  | | Vancomycin\_Hospital\_Wide | Vancomycin retrospective study, in both ICU & non-ICU patients | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | NA | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA |  | | AmphotericinB\_Hema\_ICU | Liposomal Amphotericin B (L-AmB) in ICU and Hematology patients | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | .xls | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA |  | | Fluconazole\_ICU\_IPDMA | Fluconazole in ICU individual patient data meta-analysis | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | .csv | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA |  | | Posaconazole\_ICU\_FLU | Posaconazole in ICU patients with influenza | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | .xlsx | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA |  | | Anidulafungin \_ALB\_ICU | Anidulafungin in ICU patients with Capillary Leak and Hypoalbuminemia | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | .xlsx | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA |  | | Caspofungin\_ALB\_ICU | Caspofungin in ICU patients with Capillary Leak and Hypoalbuminemia | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | .xls | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA |  | | |
| *Guidance:*  *The data description forms the basis of your entire DMP, so make sure it is detailed and complete. It includes digital and physical data and encompasses the whole spectrum ranging from raw data to processed and analysed data including analysis scripts and code. Physical data are all materials that need proper management because they are valuable, difficult to replace and/or ethical issues are associated.* *Materials that are not considered data in an RDM context include your own manuscripts, theses and presentations; documentation is an integral part of your datasets and should described under documentation/metadata.*  [*RDM Guidance on data*](https://www.kuleuven.be/rdm/en/guidance/data-standards) | |
| If you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per dataset or data type. | * M@tric: <https://www.matric.be/> * Amikacin\_ED: <https://doi.org/10.1016/j.ijantimicag.2017.11.009> * Meropenem\_ECMO\_ICU: <https://doi.org/10.3390/microorganisms9061310> * Ceftriaxone\_CAP\_ICU: <https://doi.org/10.3390/antibiotics10050557> * Vancomycin\_Hospital\_Wide: <https://doi.org/10.3390/pharmaceutics14071459> * AmphotericinB\_Hema\_ICU: <https://doi.org/10.1093/mmy/myac074> * Fluconazole\_ICU\_IPDMA: <https://doi.org/10.3390/microorganisms9102068> * Posaconazole\_ICU\_FLU: DOI: 10.1111/myc.13446 * Anidulafungin \_ALB\_ICU: the original study results have not yet been published * Caspofungin\_ALB\_ICU: the original study results have not yet been published |
| Are there any ethical issues concerning the creation and/or use of the data  (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number. | Yes, human subject data; provide SMEC or EC approval number:   * M@tric: S61364 * Amikacin\_ED: B32220109909 * Meropenem\_ECMO\_ICU: S54511 * Ceftriaxone\_CAP\_ICU: S54509 * Vancomycin\_Hospital\_Wide: S65213 * AmphotericinB\_Hema\_ICU: S59273 * Fluconazole\_ICU\_IPDMA: S62242 * Posaconazole\_ICU\_FLU: S60744 * Anidulafungin \_ALB\_ICU: S54510 * Caspofungin\_ALB\_ICU: S54510   Yes, animal data; provide ECD reference number:  Yes, dual use; provide approval number:  No  Additional information: |
| Will you process personaldata*[[4]](#footnote-4)*? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number). | Yes (provide PRET G-number or EC S-number below)   * M@tric: S61364 * Amikacin\_ED: B32220109909 * Meropenem\_ECMO\_ICU: S54511 * Ceftriaxone\_CAP\_ICU: S54509 * Vancomycin\_Hospital\_Wide: S65213 * AmphotericinB\_Hema\_ICU: S59273 * Fluconazole\_ICU\_IPDMA: S62242 * Posaconazole\_ICU\_FLU: S60744 * Anidulafungin \_ALB\_ICU: S54510 * Caspofungin\_ALB\_ICU: S54510   No  Additional information: |
| Does your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, …)?  If so, please comment per dataset or data type where appropriate. | Yes  No  If yes, please comment:  The developed models from all the datasets provide a reliable, rational predictive tool to personalize antimicrobial dosing for patients in the intensive care unit. Our personalized dosing solution can be commercialized by pharma companies, companies providing diagnostic tests, and providers of electronic health records and patient data monitoring systems. |
| Do existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material/Data transfer agreements, research collaboration agreements)?  If so, please explain to what data they relate and what restrictions are in place. | Yes  No  If yes, please explain: |
| Are there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you (re)use?  If so, please explain to what data they relate and which restrictions will be asserted. | Yes  No  If yes, please explain: |

|  |  |
| --- | --- |
| 1. **Documentation and Metadata** | |
| Clearly describe what approach will be followed to capture the accompanying information necessary to keep **data understandable and usable**, for yourself and others, now and in the future (e.g. in terms of documentation levels and types required, procedures used, Electronic Lab Notebooks, README.txt files, Codebook.tsv etc. where this information is recorded).  [*RDM guidance on documentation and metadata*](https://www.kuleuven.be/rdm/en/guidance/documentation-metadata)*.* | 1. Regarding extracted patient information, an explanation for each observed patient information (demographics, lab measurements, disease characteristics etc) will be provided. A ReadMe file of the data structure will be written. 2. Regarding the model files, the annotation will be provided following each line of the model code to explain the meaning and function of the code. A ReadMe file will be provided to illustrate the dataset used to build the model, the object (drug concentration/effect) that is being modeled, and the problem that the model aims to solve. 3. Regarding the model-derived simulation files, a ReadMe file will be provided to illustrate the model used to simulate the files as well as the information presented in the simulation file. 4. Regarding the generated R code for data individualization, the annotation will be provided following each line of the R code to explain the meaning and function of the code. |
| Will a metadata standard be used to make it easier to **find and reuse the data**?  If so, please specify which metadata standard will be used. If not, please specify which metadata will be created to make the data easier to find and reuse.  *Repositories could ask to deliver metadata in a certain format, with specified ontologies and vocabularies, i.e. standard lists with unique identifiers.* | Yes  No  If yes, please specify (where appropriate per dataset or data type) which metadata standard will be used:   * Metadata will be generated following the Dublin Core standard (https://www.dublincore.org/specifications/dublin-core/dcmi-terms/#section-1).   If no, please specify (where appropriate per dataset or data type) which metadata will be created: |

|  |  |
| --- | --- |
| 1. **Data Storage & Back-up during the Research Project** | |
| Where will the data be stored?  *Consult the*[*interactive KU Leuven storage guide*](https://icts.kuleuven.be/storagewijzer/en)*to find the most suitable storage solution for your data.* | Shared network drive (J-drive)  Personal network drive (I-drive)  OneDrive (KU Leuven)  Sharepoint online  Sharepoint on-premis  Large Volume Storage  Digital Vault  Other: |
| How will the data be backed up?  *What storage and backup procedures will be in place to prevent data loss?* | Standard back-up provided by KU Leuven ICTS for my storage solution  Personal back-ups I make (specify)  Other (specify) |
| Is there currently sufficient storage & backup capacity during the project? If yes, specify concisely. If no or insufficient storage or backup capacities are available, then explain how this will be taken care of. | Yes  KU Leuven provides free storage and backup capacity of 2 TB on OneDrive for Business for this project.  No  If no, please specify: |
| How will you ensure that the data are securely stored and not accessed or modified by unauthorized persons?  *clearly describe the measures (in terms of physical security, network security, and security of computer systems and files) that will be taken to ensure that stored and transferred data are safe.*  [*Guidance on security for research data*](https://icts.kuleuven.be/storagewijzer/en) | Sensitive data will never be allowed to be carried on unprotected personal devices. We ensure  that the processing of personal data will be fully compliant with the European Regulation 2016/679 (the General Data Protection Regulation, or "GDPR", in force from 25 May 2018), which covers the protection of personal data. |
| What are the expected costs for data storage and backup during the research project? How will these costs be covered? | There is no cost expected for the data storage. KU Leuven offers free OneDrive for Business online storage of 2 TB for every employee. |

|  |  |
| --- | --- |
| **5. Data Preservation after the end of the Research Project** | |
| Which data will be retained for at least five years (or longer, in agreement with other retention policies that are applicable) after the end of the project? In case some data cannot be preserved, clearly state the reasons for this  (e.g. legal or contractual restrictions, storage/budget issues, institutional policies...).  [*Guidance on data preservation*](https://icts.kuleuven.be/storagewijzer/en) | ​​ All data will be preserved for 10 years according to KU Leuven RDM policy  All data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for human use and for clinical experiments on humans  Certain data cannot be kept for 10 years (explain) |
| Where will these data be archived (stored and curated for the long-term)?  [*Dedicated data repositories*](https://www.kuleuven.be/rdm/en/policy)*are often the best place to preserve your data. Data not suitable for preservation in a repository can be stored using a KU Leuven storage solution, consult the*[*interactive KU Leuven storage guide*](https://www.kuleuven.be/rdm/en/guidance/data-sharing)*.* | KU Leuven RDR  Large Volume Storage (longterm for large volumes)  Shared network drive (J-drive)  Other (specifiy): |
| What are the expected costs for data preservation during the expected retention period? How will these costs be covered? | There is no cost expected for data preservation during the expected retention period. KU Leuven  offers free online storage of 2 TB on OneDrive for Business for every employee. All relevant data  will be stored under the OneDrive for Business account of the promoter (Prof. Erwin Dreesen) |

|  |  |
| --- | --- |
| **6. Data Sharing and Reuse** | |
| Will the data (or part of the data) be made available for reuse after/during the project?  Please explain per dataset or data type which data will be made available.  *Note that ‘available’ does not necessarily mean that the data set becomes openly available, conditions for access and use may apply. Availability in this question thus entails both open & restricted access. For more information:* [*https://wiki.surfnet.nl/display/standards/info-eu-repo/#infoeurepo-AccessRights*](https://wiki.surfnet.nl/display/standards/info-eu-repo/#infoeurepo-AccessRights) | Yes, as open data  Control streams, simulated datasets, and output files will be made publicly available either on a discipline-specific model repository or in the supplementary material of an article upon publication.  Yes, as embargoed data (temporary restriction)  Yes, as restricted data (upon approval, or institutional access only)  The developed pharmacometrics models & source data.  No (closed access)  Other, please specify: |
| If access is restricted, please specify who will be able to access the data and under what conditions. | The PhD student My-Luong Vuong and the promotor of this research project (Prof. Dreesen) will be  the responsible person for data preservation during and at least 5 years after the end of the  research. Internal access to those data can be granted by formal written consent provided by  Prof. Erwin Dreesen. External access to those data requires a formal data transfer agreement  with KU Leuven. |
| Are there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)? Please explain per dataset or data type where appropriate. | Yes, privacy aspects  Yes, intellectual property rights  Yes, ethical aspects  Yes, aspects of dual use  Yes, other  No  If yes, please specify: |
| Where will the data be made available?  If already known, please provide a repository per dataset or data type. | KU Leuven RDR  Other data repository (specify)  Other (specify) |
| When will the data be made available? | Upon publication of research results  Specific date (specify)  Other (specify) |
| Which data usage licenses are you going to provide? If none, please explain why.  *A data usage license indicates whether the data can be reused or not and under what conditions. If no licence is granted, the data are in a grey zone and cannot be legally reused. Do note that you may only release data under a licence chosen by yourself if it does not already fall under another licence that might prohibit that.*  *Check the*[*RDR guidance on licences*](https://www.kuleuven.be/rdm/en/rdr/licenses)*for data and software sources code or consult the*[*License selector tool*](https://ufal.github.io/public-license-selector/)*to help you choose.* | CC-BY 4.0 (data)  Data Transfer Agreement (restricted data)  MIT licence (code)  GNU GPL-3.0 (code)  Other (specify) |
| Do you intend to add a PID/DOI/accession number to your dataset(s)? If already available, please provide it here.  *Indicate whether you intend to add a persistent and unique identifier in order to identify and retrieve the data.* | Yes, a PID will be added upon deposit in a data repository  My dataset already has a PID  No |
| What are the expected costs for data sharing? How will these costs be covered? | There is no cost for sharing the data within KU Leuven. The cost of sharing data with external  parties needs to be covered by the external parties. |

|  |  |
| --- | --- |
| **7. Responsibilities** | |
| Who will manage data documentation and metadata during the research project? | The PhD student My-Luong Vuong himself. |
| Who will manage data storage and backup during the research project? | The PhD student My-Luong Vuong himself. |
| Who will manage data preservation and sharing? | The promotor of this research project (prof. Dreesen). |
| Who will update and implement this DMP? | The PhD student My-Luong Vuong himself. |

1. “Project number” refers to the institutional project number. This question is optional. Applicants can only provide one project number. [↑](#footnote-ref-1)
2. Funder(s) GrantID refers to the number of the DMP at the funder(s), here one can specify multiple GrantIDs if multiple funding sources were used. [↑](#footnote-ref-2)
3. Add rows for each dataset you want to describe. [↑](#footnote-ref-3)
4. See Glossary Flemish Standard Data Management Plan [↑](#footnote-ref-4)